### RANDOX

### **DIABETES PORTFOLIO**



HIGH QUALITY TESTS FOR THE DIAGNOSIS OF DIABETES AND MONITORING OF ASSOCIATED COMPLICATIONS



### **DIABETES PORTFOLIO**

Diagnosis & Monitoring | Complications Monitoring

	01	BENEFITS	
	02	INTRODUCTION	
	03	DIAGNOSIS & MONITORIN	IG
	07	COMPLICATIONS & MONI	TORING
	20	ORDERING INFORMATION	٨
	26	PORTFOLIO OF REAGENT	S
	27	RANDOX - A GLOBAL DIA SOLUTIONS PROVIDEER	GNOSTIC
	28	CONTACT US	
Key:	UF	UNIQUE feature When you see this symbol you will know that this feature is unique to	NICHE product When you see this symbol you will know that Bandox have one of the only
		the Randox product	automated biochemistry assays available

on the market

### **Benefits of Randox Reagents**

Randox offers an extensive range of third party diagnostic reagents which are internationally recognised as being of the highest quality; producing accurate and precise results. We have an extensive test menu of 100 assays, covering over 100 disease markers including: antioxidants, diabetes, cardiology & lipid testing, clinical chemistry, specific proteins, therapeutic drug monitoring and veterinary testing. A wide range of formats and methods are available providing greater flexibility and choice for any laboratory size. In addition to flexible pack sizes and a comprehensive list of analyser applications, we can also provide dedicated reagent packs (Randox Easy Read and Easy Fit regents) for a wide range of clinical chemistry analysers, providing you with freedom of choice from an independent manufacturer.



### Expand your test menu without expanding your lab

There is no need to buy any extra equipment in order to expand your test menu. Our reagents can be programmed onto the majority of the most common clinical chemistry analysers.



### Expand routine testing

With speciality assays for 195 of the most common clinical chemistry analysers; assays which usually require dedicated equipment (or was previously only available as an ELISA) can now be run on automated clinical chemistry analysers; allowing your laboratory to expand its routine test menu.



### **Reduce costs**

We can help create cost-savings for your laboratory through excellent reagent stability; excellent quality of products (eliminating costly re-runs) and by offering a range of kit sizes (including smaller kit sizes for niche tests, reducing waste).

### Bring testing in-house

With smaller kit sizes and excellent reagent stability (most are stable for 28 days onboard the analyser), you don't have to worry about reagent wastage, allowing testing to be brought in-house.



### Bring testing in-house

With smaller kit sizes and excellent reagent stability (most are stable for 28 days onboard the analyser), you don't have to worry about reagent wastage, allowing testing to be brought in-house.

ଡ଼

### Reduce the risk of errors and have confidence in patient results

Our traceability of material and extremely tight manufacturing tolerances ensure uniformity across reagent batches reducing lot-to-lot variability. All our assays are validated against gold-standard methods, offering low % CV's and excellent precision giving you the confidence that you are sending out the correct patient results.

### Introduction

Randox is committed to advancing diabetes testing, including the associated complications. In doing so, Randox offers a comprehensive range of high quality reagents ranging from diabetes risk assessment to the diagnosis and monitoring of diabetes, to the diagnosis and monitoring of associated complications. The Randox diabetes portfolio covers the full spectrum of clinical biochemistry laboratory testing requirements including several niche and superior performance assays.

Type 2 diabetes mellitus (T2DM) has reached epidemic levels, now attaining the status of global pandemic, spreading from developed countries to developing countries. The burden on healthcare systems and epidemiological trends indicate that the prevalence will continue to increase dramatically in the coming years. The prevalence, mortality and morbidity rates of T2DM can be reduced and progression halted or slowed with early diagnosis and treatment1. According to the World Health Organization (WHO), diabetes is estimated to be the seventh leading cause of death globally with 1.6 million deaths attributed to diabetes in 2016<sup>2</sup>.

Not only does Randox offer assays, diagnosis and monitoring of diabetes, but we also offer assays for the monitoring of associated complications including: renal dysfunction, ketoacidosis and metabolic status.

Diabetic nephropathy (diabetic kidney disease) is a serious complication of T2DM, affecting a third of T2DM patients. The kidneys are vital organs in glycaemic control as they contribute to tubular reabsorption of glucose and gluconeogenesis. Not only has outpatient care increased due to diabetic nephropathy, but hospital visits, in-hospital stays and mortality rates have also increased. Moreover, diabetic nephropathy has also increased the demand for renal replacement therapies including dialysis and kidney transplants <sup>3</sup>.

Diabetic ketoacidosis (DKA) is a serious complication of both Type I Diabetes Mellitus (T1DM) and T2DM and often marks the beginning of diabetes onset, accounting for 6% of cases. DKA is an extreme metabolic state attributed to both relative and absolute insulin deficiency. Insulin deficiency causes lipolysis (breakdown of fatty acids) and ketogenesis (production of ketones). Acidosis occurs when the acidic ketone bodies are excessive <sup>4</sup>.

Metabolic status is a key area in determining diabetes risk. Those who are metabolically unhealthy, including metabolic abnormalities, are at a greater risk of T2DM compared to those who are defined as metabolically healthy, irrespective of obesity / BMI status <sup>5, 6</sup>.

1. Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V. Type 2 Diabetes: Demystifying the Global Epidemic.. Diabetes 2017; 66(6): 1432-1442.

2. World Health Organization (WHO). Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes (accessed 2 May 2019)

3. Pecoits-Filho R, Abensur H, Abensur H, Betonico CC, Machado AD, Parente EB, et al.. Interactions between kidney disease and diabetes: dangerous liaisons. Diabetology & Metabolic Syndrome 2016; 8(50): 1758-5996.

4. Misra S, Oliver NS. Diabetic ketoacidosis in adults. British Medical Journal (BMJ) 2015; 351(): https://www.bmj.com/content/351/bmj.h5660 (accessed 5 August

2019).

5. Rhee EJ, Lee MK, Kim JD, Jeon WS, Bae JC, Park SE, et al.: Metabolic Health Is a More Important Determinant for Diabetes Development than Simple Obesity: A 4-Year Retrospective Longitudinal Study. A Peer-Reviewed, Open Access Journal (PLoS One) 2014; 9(5): https://journals.plos.org/plosone/ article?id=10.1371/journal.pone.0098369 (accessed 7 August 2019 ).

6. Janghorbani M, Salamat MR, Amini M, Aminorroaya A. Risk of diabetes according to the metabolic health status and degree of obesity. Diabetic & Metabolic Syndrome 2017; 11(1): 439-444.

### DIAGNOSIS & MONITORING

Glucose / HbA1c (Indirect) / Fructosamine (Glycated Protein)

### Glucose

### Key Benefits of the Randox Glucose Assay

- GOD-PAP and Hexokinase methods available, satisfying individual laboratory testing preferences.
- Wide measuring range of 0.200 35.5mmol/l, comfortably detecting levels outside of the healthy range.
- **Exceptional correlation** coefficient of r=0.99 when compared against other commercially available methods.
- Calibrator and controls available offering a complete testing package.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox glucose assay on a wide range of clinical chemistry analysers.

#### **Biological Significance**

Glucose is a fundamental metabolic substrate for tissue energy production. Glucose falls under three classifications: monosaccharide, hexose and aldose. Half of the total carbohydrates consumed through diet are polysaccharides which are hydrolysed to monosaccharides. Glucose is regulated within the body at a stable concentration, however, conditions such as diabetes increase glucose concentrations <sup>1</sup>.

#### **Clinical Significance**

It is well-known that strict glycaemic control can prevent secondary complications. Numerous studies highlight that hyperglycaemia is an independent and clinically significant risk factor for CVD 2. A patient is diagnosed with diabetes if blood glucose levels are >125mg/dl. If left untreated, hyperglycaemia can result in serious and life-threatening complications including: CVD, hepatic impairment, renal impairment and diabetic eye disease <sup>3</sup>.

1. McMillin JM. Clinical Methods: The History, Physical, and Laboratory Examinations. Boston: Butterworths; 1990. https://www.ncbi.nlm.nih.gov/books/NBK248/ (accessed 31 July 2019).

- 2. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Archives of Internal Medicine 2003; 163(11): 1306-1316.
- 3. Mouri M, Badireddy M. Hyperglycemia. Treasure Island: StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK430900/ (accessed 31 July 2019).

### HbA1c (Indirect)

### Key Benefits of the Randox HbA1c Assay

- Latex enhanced immunoagglutination method delivering high performance.
- **Exceptional correlation** coefficient of r=0.98 when compared against other commercially available methods.
- **Excellent precision** of <5% CV.
- **Dedicated calibrator and controls available** offering a complete testing package.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox HbA1c assay on a wide range of clinical chemistry analysers.

A direct HbAIc assay is available for the RX series only. The direct HbAIc assay is certified by the National Glycohemoglobin Standardization Program (NGSP) for the RX daytona+, RX imola and RX modena.

### **Biological Significance**

Haemoglobin is a protein found in red blood cells (RBC's). The role of haemoglobin is to transport oxygen around the body. When glucose levels increase, it binds to the haemoglobin in RBC's. HbA1c levels reflect the average blood sugar levels for the preceding 2 to 3 months; making HbA1c an ideal marker of long-term glucose monitoring <sup>1</sup>.

### **Clinical Significance**

HbA1c testing is utilised in the diagnosis and monitoring of diabetes as it highlights how much glucose is bound to the RBC's. When monitoring diabetes, the HbA1c test is utilised to ensure glucose levels remain within the normal range. Moreover, high HbA1c levels increase the risk of associated complications. The target value for those with diabetes is usually <7%. Fig 2 provides a visual representation of the HbA1c testing criterion <sup>1</sup>.



1. WebMD. Hemoglobin A1c (HbA1c) Test for Diabetes. https://www.webmd.com/diabetes/guide/glycated-hemoglobin-test-hba1c (accessed 31 July 2019).

### Fructosamine (Glycated Protein)

### Key Benefits of the Randox Fructosamine (Glycated Protein) Assay

- **Enzymatic method** offering improved specificity and reliability compared to conventional NBT-based methods. The Randox enzymatic method does not suffer from non-specific interferences unlike the existing methods which can also be time-consuming and difficult to automate.
- **Standardisation to the highest level** as the Randox calibrator and controls are assigned relative to human serum glycated with 14C glucose, directly reflecting the nature of the patient sample.
- **Excellent stability** on board the analyser when stored at +10°C.
- **Dedicated calibrator and controls available** offering a complete testing package.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox fructosamine assay on a wide range of clinical chemistry analysers.

#### **Biological Significance**

In a diabetic patient where blood glucose levels are abnormally elevated, the concentration of fructosamine (glycated protein) also increases as fructosamine is formed by a non - enzymatic Maillard reaction between glucose and amino acid residues of proteins. During this glycation process, an intermediate labile Schiff base is produced which is converted to a more stable ketoamine (fructosamine) via an Amadori rearrangement <sup>1</sup>.

### **Clinical Significance**

Fructosamine (glycated protein) has been identified as an early indicator of diabetic control compared to other markers such as HbA1c. RBCs live for approximately 120 days. HbA1c represents the average blood glucose levels for the previous 2 to 3 months. Conversely, fructosamine has a shorter lifespan, of about 14 to 21 days, reflecting average blood glucose levels from the previous 2 to 3 weeks <sup>2</sup>. Fructosamine testing has been identified as being the best for patient care as HbA1c results can be inconclusive for several reasons. Genetic, haematological and disease-related factors negatively impact HbA1c levels, with low levels observed in late stage chronic kidney disease, conditions that shorten the lifespan of erythrocytes such as haemolytic anaemia, and in certain haemoglobinopathies such as sickle cell disease. In gestational diabetes, fructosamine should be tested as HbA1c levels are difficult to interpret as HbA1c integrates glycaemia over the lifespan of the erythrocyte. Therefore, HbA1c is relatively insensitive to short term changes. Consequently, HbA1c testing isn't suitable in the monitoring of the effects of changes in medication. Fructosamine is a medium-term marker (shorter life span) and is a much more suitable test <sup>3</sup>.

<sup>1.</sup> Gounden V, Jialal I. Fructosamine. Treasure Island: StatPearls Publishing; 2019. https://www.ncbi.nlm.nih.gov/books/NBK470185/ (accessed 31 July 2019).

<sup>2.</sup> Manzella, D. What Is the Fasting Plasma Glucose Test?. https://www.verywellhealth.com/understanding-the-fasting-plasma-glucose-test-1087680 (accessed 31st July 2019).

<sup>3.</sup> Rodriguez-Segade S, Rodriguez J, Camiña F. Corrected fructosamine improves both correlation with HbA1c and diagnostic performance. Clinical Biochemistry 2017; 50(2017): 110-115.

# **COMPLICATIONS &** MONITORING Renal Dysfunction Cystatin C | Creatinine (Enzymatic) | Creatinine (Jaffe) | Microalbumin Albumin | B2Microglobulin (B2M)

### Cystatin C 🛛

### Key Benefits of the Randox Cystatin C Assay

- Latex enhanced immunoagglutination method delivering high performance.
- **Exceptional correlation** coefficient of r=1.00 when compared against commercially available methods.
- Excellent precision of <6.2% CV.
- **Dedicated calibrator and controls available** offering a complete testing package.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox cystatin C assay on a wide range of clinical chemistry analysers.

### **Biological Significance**

Cystatin C is a 122 - amino acid, 13.3kDa cysteine proteinase inhibitor, fashioned by all nucleated cells at a constant rate. Cystatin C travels through the bloodstream to the kidneys where it is freely filtered by the glomerular membrane, resorbed and fully catabolised by the proximal renal tubes. Cystatin C is a sensitive biomarker for GFR function <sup>1,2</sup>.

#### **Clinical Significance**

Cystatin C has been identified as a stronger predictor of clinical outcomes associated with chronic kidney disease (CKD) compared to creatinine <sup>3</sup>. Cystatin C levels inversely correlates with the GFR function. Cystatin C measurements are unaffected by non - renal factors such as muscle mass, sex, age and race, unlike creatinine <sup>4</sup>. The main disadvantage of using creatinine to screen for renal impairment is that up to 50% of renal function can be lost before significant creatinine levels become detectable. Cystatin C does not have a 'blind area' and is highly sensitive to small changes in GFR enabling early detection of renal impairment <sup>5</sup>.

The National Institute for Health and Care Excellence (NICE) UK have updated their chronic kidney disease in adults: assessment and management guidelines, recommending cystatin C testing due to its higher specificity for significant disease outcomes than those based on creatinine <sup>6</sup>. More reliable and robust eGFR measurements produced from Cystatin C testing will mitigate the burden of incorrectly staged and misdiagnosed CKD patients <sup>7</sup>. NICE recommend using eGFR cystatin C when a patient has an eGFR creatinine of 45 - 53ml/min/1.73 m<sup>2</sup>, sustained for a minimum of 90 days and no proteinuria or other marker of kidney disease is present <sup>6</sup>.

1. Murty MS, Sharma UK, Pandey VB, Kankare SB. Serum cystatin C as a marker of renal function in detection of early acute kidney injury. Indian Journal of Nephrology 2013; 23(3): 180-183.

2. Chew JS, Saleem M, Florkowski CM, George PM. Cystatin C–A Paradigm of Evidence Based Laboratory Medicine. The Clinical Biochemist Reviews 2008; 29(2): 47-62.

3. Peralta CA, Katz R, Sarnak MJ, Ix J, Fried LF, De Boer I, et al.. Cystatin C identifies chronic kidney disease patients at higher risk for complications1. Journal of the American Society of Nephrology 2011; 22(1): 147-155.

4. Fiseha T. Clinical Significance of Cystatin C-Based Estimates of Renal Function in Type 2 Diabetic Patients: Review. Annals of Clinical and Laboratory Research 2015; 3 (2:11).

5. Mishra U. New technique developed to detect chronic kidney disease. https://www.thehindubusinessline.com/news/science/new-technique-to-detect-chronic-kidney-disease/article23803316.ece# (accessed 6 March 2020).

6. National Institute for Health and Care Excellence (NICE). Chronic kidney disease in adults: assessment and management, https://www.nice.org.uk/guidance/cg182/chapter/2-Implementation-getting-started (accessed 6 March 2020).

7. Krishnamurthy N. Biochemistry. Biochemistry and Analytical Biochemistry 2017; 6(3 (Suppl)): 54.

8

### Creatinine Enzymatic & Jaffe

### Key Benefits of the Randox Enzymatic Creatinine Assay

- **Enzymatic UV method** delivering high performance.
- **Excellent stability** of 30 days when stored at +2 to +8°C.
- **Excellent measuring range** of 11.4-2460µmol/l for the comfortable detection of clinically important results.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox enzymatic creatinine assay on a wide range of clinical chemistry analysers.
- **Calibrator and controls available** offering a complete testing package.

### Key Benefits of the Randox Jaffe Creatinine Assay

- **Excellent open vial stability** of 21 days when stored in a refrigerator at +2 to +8°C.
- **Excellent measuring range** of 16 2448µmol/l for the comfortable detection of clinically important results.
- Liquid ready-to-use reagents for convenience and ease-of-use.
- Calibrator and controls available offering a complete testing package.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox jaffe creatinine assay on a wide range of clinical chemistry analysers.

### **Biological Significance**

Creatinine is the end-product of muscle catabolism of creatine. In humans, creatinine production is relatively stable, but mainly depends on muscles mass. Consequently, any physiological changes in muscle mass will cause a variation in the creatinine pool independently of GFR changes. Creatinine is freely filtered by the glomerulus at a constant rate with 10% to 40% secreted by the tubules <sup>1</sup>.

### **Clinical Significance**

Creatinine measurements are useful in the diagnosis and monitoring of diabetic nephropathy, the leading cause of kidney disease in patients commencing renal replacement therapy, affecting 40% of diabetics (type 1 and type 2)<sup>2</sup>. The RENAAL risk score for end-stage renal disease (ESRD) emphasizes the importance of the identification of elevated SCr, alongside other renal markers, in the prediction of end-stage renal disease (ESRD) development in patients with type 2 diabetes mellitus (T2DM) and nephropathy<sup>3</sup>.

3. Dabla PK. Renal function in diabetic nephropathy. World Journal of Diabetes 2010; 1(2): 48-56.

<sup>1.</sup> Bargnoux AS, Kuster N, Cavalier E, Piéroni L, Souweine JS. Serum creatinine: advantages and pitfalls. Journal of laboratory and Precision Medicine 2018; 3(71): 1-7.

<sup>2.</sup> Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, et al. Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care 2005; 28(1): 164-176.

### Microalbumin

### Key Benefits of the Randox Microalbumin Key Assay

- Calibrator supplied with kit simplifying the ordering process.
- **Exceptional correlation** coefficient or r=0.99 when compared against other commercially available methods.
- **Extensive range** of 4.06 396mg/l for the comfortable detection of clinically important results.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox microalbumin assay on a wide range of clinical chemistry analysers.
- **Dedicated calibrator** and control available offering a complete testing package.

#### **Biological Significance**

Albumin is one of the major plasma proteins and is usually present in very low concentrations in urine. Damage to the glomerular basement membrane can alter its permeability meaning albumin and other proteins usually reabsorbed and recirculated in the blood enter the urine. Sustained elevations of urinary albumin concentrations are called microalbuminuria <sup>1</sup>.

### **Clinical Significance**

Microalbumin is strongly associated with poor glycaemic control, hypertension and other diabetic complications including ischaemic heart disease, diabetic retinopathy and neuropathy. Microalbumin is an early biomarker of diabetic nephropathy, the most common complication of T2DM <sup>2</sup>.

<sup>1.</sup> Lab Tests Online UK. Urine Albumin to Creatinine Ratio or ACR. https://labtestsonline.org.uk/tests/urine-albumin-creatinine-ratio-or-acr (accessed 27 November 2018).

<sup>2.</sup> Ahmad T, Ulhaq I, Mawani M, Islam N. Microalbuminuria in Type-2 Diabetes Mellitus; the tip of iceberg of diabetic complications. Pakistan Journal of Medical Sciences 2017; 33(3): 519-523.

### B2Microglobulin (B2M)

### Key Benefits of the Randox B2M Assay

- Wide measuring range of 0.476 20.9mg/l for the comfortable detection of clinically important results.
- Stable to expiry date when stored at +2 to +8°C.
- Liquid ready-to-use reagents for convenience and ease-of-use.
- Calibrator and controls available offering a complete testing package.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox B2M assay on a wide range of clinical chemistry analysers.

### **Biological Significance**

 $B_2M$  is a small (11,800Da) protein located on the surface of nucleated cells and most biological fluids, including: synovial fluid, urine and serum, and is especially abundant in monocytes and lymphocytes <sup>1,2</sup>. Under normal conditions, intracellular release causes small amounts of  $B_2M$  to be released into the blood which is then filtered and removed via the kidneys. The concentration levels of  $B_2M$  is determined by two factors: generation and secretion into circulation and elimination via the kidneys. Elevated cell turnover and/or renal impairment are the two contributing factors to elevated  $B_2M$  concentrations <sup>2</sup>.

### **Clinical Significance**

Elevated  $\beta_2M$  concentrations have been observed in autoimmune, immunodeficiency and renal diseases<sup>2</sup>.  $\beta_2M$  has been identified as a strong marker in the assessment of tubular and glomerular function in adults. It has been recognised that  $\beta_2M$  testing offers similar estimating equations as creatinine, however,  $\beta_2M$  appears to be more strongly associated with cardiovascular mortality and morbidity compared to creatinine or other renal markers.  $\beta_2M$  is reliable and cost - effective, making it the ideal screening tool for diabetic nephropathy <sup>3</sup>.

1. Li L, Dong M, Wang XG. The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator. Clinical Medical Journal 2016; 129(4): 448-455.

2. Prizment AE, Linabery AM, Lutsey PL, Selvin E, Nelson HH, Folsom AR, et al.. Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC). Cancer Epidemiology, Biomarkers & Prevention 2016; 25(4): 657-664.

3. Argyropoulos CP, Chen SS, Ng YH, Roumelioti ME, Shaffi K, Singh PP. Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Frontiers in Medicine 2017; 4(): 73.



### D - 3 - Hydroxybutyrate (Ranbut)

### Key Benefits of the Randox D - 3 - Hydroxybutyrate (Ranbut) Assay

- Superior methodology when compared to other commercially available ketone detection tests. For example, the nitroprusside method used in semi-quantitative dipstick tests only detects acetone and acetoacetate. D - 3 - hydroxybutyrate is the most abundant ketone produced during ketosis the measurement of this analyte is more sensitive and specific.
- **Exceptional correlation** coefficient of r=0.9954 when compared against other commercially available methods.
- **Excellent precision** of <3.5% CV.
- Calibrator and controls available offering a complete testing package.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox D 3 -Hyroxybutyrate (Ranbut) assay on a wide range of clinical chemistry analysers.
- New liquid stable Ranbut assays available

#### **Biological Significance**

During prolonged periods of starvation or impaired carbohydrate metabolism, starved cells begin to signal for energy from fat metabolism. Ketone bodies (acetoacetate, D-3-hydroxybutyrate and acetone) are produced from fatty acid beta-oxidation; a process called ketosis which takes place in the liver. Of the three ketones, D-3-hydroxybutyrate is the major ketone in the body <sup>1,2</sup>.

#### **Clinical Significance**

Ketosis produces ketones which is not normally dangerous. If left untreated, especially in diabetes, ketoacidosis (high levels of ketones) develops which can be fatal and damage the liver and kidneys <sup>3</sup>. In type 1 diabetes mellitus (T1DM), the body is unable to produce insulin resulting in bodily cells not receiving energy from glucose, causing the body to release hormones to breakdown fat for energy, producing ketones. Diabetic ketoacidosis is commonly triggered by an illness, infection or missing insulin treatments <sup>4</sup>.

1. Hsu WS, Kao JT, Tsai KS. Fully automated assay of blood D-3-hydroxybutyrate for ketosis. Journal of Formosan Medical Association 1993; 92(4): 336-340.

2. Vigili de Kreutzenberg S, Avogaro A. The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography. Journal of

Endocrinological Investigation 2017; 40(6): 627-634

3. Hecht M. Ketosis vs. Ketoacidosis: What You Should Know. https://www.healthline.com/health/ketosis-vs-ketoacidosis (accessed 6 August 2019).

4. Mayo Clinic. Diabetic ketoacidosis. https://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/symptoms-causes/syc-20371551 (accessed 6 August 2019).

## COMPLICATIONS & MONITORING

Metabolic Status | Non - Esterified fatty acids (NEFA)

### Non - Esterified Fatty Aids (NEFA)

### Key Benefits of the Randox NEFA Assay

- **Exceptional correlation coefficient** of r=0.98 when compared against other commercially available methods.
- Excellent precision of <5% CV.
- **Extensive measuring range** of 0.072 2.24mmol/l for the comfortable detection of clinically important results.
- Calibrator and controls available offering a complete testing package.
- **Applications available** detailing instrument-specific settings for the convenient use of the Randox NEFA assay on a wide range of clinical chemistry analysers.

#### **Biological Significance**

NEFA are important metabolites stored in adipose tissue. NEFA turnover is swift, with a plasma half - life of 2 to 4 minutes. The dominant source of NEFA is abdominal subcutaneous fat, with considerably less found in leg adipose tissue and a small proportion found in the intra-abdominal adipose tissue. NEFA has been recognised as a vehicle by which triacylglycerol (TG) (stored in the adipose tissue) is transported to its sites of utilisation <sup>1</sup>. NEFA has been identified as the major energy source for skeletal muscle during fasting stages and long periods between meals. Cross - sectional studies have consistently documented that circulating NEFA levels are proportional to body fat storage and demonstrated positive correlations between fasting NEFA levels and obesity, insulin resistance and glucose tolerance <sup>2</sup>.

#### **Clinical Significance**

NEFA concentrations are strongly associated with insulin resistance. In the fasting state, the resistance of adipose tissue to the antilipolytic effect of insulin causes the extensive release of NEFA into circulation. Elevated NEFA levels exacerbate insulin resistance through diminishing insulin - stimulated glucose intake into the skeletal muscle, directly affecting insulin signalling <sup>3</sup>.

1. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011; 60(10): 2441-2449.

2. Il'yasova D, Wang F, D'Agostino RB Jr, Hanley A, Wagenknecht LE. Prospective association between fasting NEFA and type 2 diabetes: impact of post-load glucose. Diabetologia 2010; 53(5): 866-874.

3. Saad MJ, Kamel MA, Hanafi MY. Modulation of Adipocytokines Production and Serum NEFA Level by Metformin, Glimepiride, and Sitagliptin in HFD/STZ Diabetic Rats. Biochemistry Research International 2015; 2015(138134): . https://www.hindawi.com/journals/bri/2015/138134/ (accessed 7 August 2019). **ORDERING INFORMATION** 

\_

Description	Method	Size	Cat. No.
Albumin	BCG	6 x 100ml (S)♦	AB362
Albumin	BCG	9 x 51ml <b></b>	AB3800
Albumin	BCG	4 x 68ml♦	AB8000
Albumin	BCG	4 x 20ml∳	AB8301
ß2Microglobulin	L.E.I	R1 2 x 11ml∳ R2 2 x 4.3ml	BM3887
Creatinine	Jaffe	1 x 200ml (S)∳	CR510
Creatinine	Jaffe	R1 6 x 51ml♦ R2 3 x 28ml	CR3814
Creatinine	Jaffe	R1 6 x 68ml <b></b> R2 6 x 20ml	CR8022
Creatinine	Enzymatic UV	R1 4 x 20ml <b></b> R2 4 x 7ml	CR8316
Creatinine	Enzymatic UV	R1 4 x 50ml (S) R2 4 x 10ml	CR2336
Creatinine	Enzymatic UV	R1 4x50ml <b></b> R2 4x19.5ml	CR4037

 $\left( C\right)$  indicates calibrator included in kit

(S) indicates standard included in kit

♦ indications liquid option

17

Description	Method	Size	Cat. No.
Creatinine	Enzymatic UV	R1 4 x 100ml (S) R2 4 x 20ml	CR2337
Creatinine	Enzymatic UV	R1 4 x 65ml <b></b> R2 4 x 32.3ml	CR8122
Creatinine	Enzymatic UV	R1 4 x 20ml <b></b> R2 4 x 9.5ml	CR8317
Cystatin C	L.E.I	R1 2 x 17.6ml <b></b> R2 2 x 6.1ml	CYS4004
D - 3 - Hydroxybutyrate (Ranbut)	Enzymatic	10 x 10ml (S)	RB1007
D - 3 - Hydroxybutyrate (Ranbut)	Enzymatic	10 x 50ml (S)	RB1008
D - 3 - Hydroxybutyrate (Ranbut)	Enzymatic	R1 2 x 20ml <b></b> R2 2 x 5.8ml	RB4067
D - 3 - Hydroxybutyrate (Ranbut)	Enzymatic	R1 2 x 20ml <b></b> R2 2 x 6.1ml	RB8378
Fructosamine (Glycated Protein)	Enzymatic	R1 5 x 25ml <b></b> R2 5 x 6.3ml	FR3133
Fructosamine (Glycated Protein)	Enzymatic	R1 4 x 19.8ml♦ R2 4 x 6.9ml	FR4030
Glucose	GOD-PAP	4 x 68ml∳	GL8038

 $\left( C\right)$  indicates calibrator included in kit

(S) indicates standard included in kit

 $\blacklozenge$  indications liquid option

18

\_

Description	Method	Size	Cat. No.
Glucose	GOD-PAP	10 x 100ml (S)	GL364
Glucose	GOD-PAP	4 x 20ml <b></b>	GL3981
Glucose	GOD-PAP	2 x 500ml (S)♦	GL2614
Glucose	GOD-PAP	9 x 51ml <b></b>	GL3815
Glucose	GOD-PAP	4 x 20ml <b></b>	GL8318
Glucose	Hexokinase	4 x 50ml	GL3881
Glucose	Hexokinase	R1 4 x 51ml <b></b> R2 3 x 20ml	GL3816
Glucose	Hexokinase	R1 4 x 20ml∳ R2 4 x 6.5ml	GL8319
HbA1c (Indirect)	Latex Immunoagglutination	R1 3 x 14ml <b></b> R2 3 x 14ml	HA3830
HbA1c (Indirect)	Latex Immunoagglutination	R1 4 x 7.8ml♦ R2 4 x 7.8ml	HA8321
HbA1c Indirect Haemoglobin Denatured Reagent Denatured Reagent	Latex Immunoagglutination	2 x 50ml <b></b>	HA3450

 $\left( C\right)$  indicates calibrator included in kit

(S) indicates standard included in kit

♦ indications liquid option

Description	Method	Size	Cat. No.
HbA1c II Direct	Latex Immunoagglutination	R1 4 x 16.2ml R2 2 x 8.2ml	HA8123
HbA1c II Direct	Latex Immunoagglutination	R1 4 x 12.7ml♦ R2 4 x 6ml	HA8379
HbA1c II Direct	Latex Immunoagglutination	R1 4 x 20ml <b></b> R2 4 x 8.6ml	HA4068
Microalbumin	PEG Enhanced Immunoturbidimetric	R1 1 x 60ml (C)∙ R2 1 x 7ml	MA2426
Microalbumin	PEG Enhanced Immunoturbidimetric	R1 6 x 20ml <b></b> R2 3 x 8ml	MA3828
Microalbumin	PEG Enhanced Immunoturbidimetric	R1 2 x 20ml <b></b> R2 2 x 6.6ml	MA8056
Microalbumin	PEG Enhanced Immunoturbidimetric	R1 1 x 20ml <b>●</b> R2 1 x 4.6ml	MA8325
Microalbumin 2	PEG Enhanced Immunoturbidimetric	R1 3 x 20ml <b></b> R2 3 x 7.5ml	MA4072
Microalbumin 2	PEG Enhanced Immunoturbidimetric	R1 2 x 20ml <b></b> R2 2 x 9ml	MA8160
Microalbumin 2	PEG Enhanced Immunoturbidimetric	R1 1 x 20ml <b></b> R2 1 x 7.8ml	MA8388

 $\left( C\right)$  indicates calibrator included in kit

(S) indicates standard included in kit

 $\blacklozenge$  indications liquid option

Description	Method	Size	Cat. No.
NEFA	Colorimetric	R1 3 × 10ml (C)∳ R2 3 × 20ml	FA115

(S) indicates standard included in kit

• indications liquid option



### **Portfolio of Reagents**

### **Diabetes Portfolio**

Reagent	Page No
Albumin	17
Creatinine	17-18
Cystatin C	18
D - 3 - Hydroxybutyrate (Ranbut)	18
Fructosamine (Glycated Serum Protein)	18
ß2Microglobulin (ß2M)	11

Reagent	Page No
Glucose	18-19
HbA1c, Direct	20
HbA1c, Indirect	19
Microalbumin	20
Non-Esterified Fatty Acids (NEFA)	21

#### UTHER ASSATS AVAILABLE FRUM RANDUX

Aldolase
Alkaline Phosphatase
Alanine Aminotransferase (ALT)
Ammonia
Amylase
Amylase Pancreatic
Anti-Streptolysin O (ASO)
Apolipoprotein A-I
Apolipoprotein A-II
Apolipoprotein B
Apolipoprotein C-II
Apolipoprotein C-III
Apolipoprotein E
Aspartate
Aminotransferase (AST)
Bile Acids, 4th Gen
Bile Acids, 5th Gen
Bilirubin, Direct
Bilirubin, Total
Calcium
Carbamazepine
Cholesterol, Total
Cholesterol, HDL

Cholesterol, LDL Cholesterol, sdLDL Cholinesterase (Butyryl) CK-MB CK-NAC CO2 Total Complement C3 Complement C4 Copper CRP CRP, Canine CRP, Full Range CRP, High Sensitivity Digoxin Ferritin G6PDH Gamma GT Gentamicin GLDH Glutamate Glutathione Peroxidase (Ransel) Glutathione Reductase Glycerol

Haemoglobin	Soluble Transferrin Receptor
Haptoglobin	(strR)
Heart-type Fatty Acid	Superoxide Dismutase (Ransod)
Binding Protein (H-FABP)	Syphilis
Homocysteine	Total Antioxidant Status (TAS)
IgA	Total Iron Binding Capacity
IgE	
lgG	Iotal Protein
lgM	Transferrin
Iron	Transthyretin (Prealbumin)
L-Lactate	Triglycerides
Lactate Dehvdrogenase	Urea
(L-P)	Uric Acid
Lactate Dehydrogenase	Urinary Protein
(P-L)	Valproic Acid
Lipase	Zinc
Lipoprotein(a)	
Magnesium	
Myoglobin	
Phenobarbital	
Phenytoin	
Phosphorus (Inorganic)	
Potassium	
Rheumatoid Factor (RF)	
Sodium	

# Randox - a global diagnostic solutions provider

Randox has been supplying laboratories worldwide with revolutionary diagnostic solutions for over 40 years. Our experience and expertise allow us to create a leading product portfolio of high quality diagnostic tools which offer reliable and rapid diagnosis.

We believe that by providing laboratories with the right tools, we can improve health care worldwide.

### **RX SERIES**

Renowned for quality and reliability, the RX series combines robust hardware and intuitive software with the world leading RX series test menu comprising an extensive range of high quality reagents including routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants and diabetes testing. The RX series offers excellence in patient care delivering unrivalled precision and accuracy for results you can trust, guaranteeing real cost savings through consolidation of routine and specialised tests onto one single platform.

### INTERNAL QUALITY CONTROL

Acusera third party quality controls are made using the highest quality material of human origin, ensuring they react like a real patient sample. With more than 390 analytes available across the Acusera range we can uniquely reduce the number of controls required while reducing costs and time. Our product range includes clinical chemistry, immunoassay, urine, immunology and more. Qnostics molecular controls for infectious disease testing are designed to meet the demand of today's molecular diagnostics laboratory while effectively monitoring the entire testing process. Our whole pathogen molecular controls comprise hundreds of characterised viral, bacterial and fungal targets.

### EXTERNAL QUALITY ASSESSMENT

RIQAS is the world's largest international EQA scheme with more than 47,000 participants worldwide. 33 comprehensive, yet flexible programmes cover a wide range of clinical diagnostic testing including chemistry, immunoassay, cardiac, urine, serology and more. Our programmes benefit from a wide range of concentrations, frequent reporting, rapid feedback and user-friendly reports. The QCMD range of molecular infectious disease EQA programmes feature a whole pathogen matrix ensuring a true test of patient sample analysis. With access to over 90 programmes including blood borne viruses, respiratory diseases, multi-pathogen infections and more, there is something for every laboratory.



### **EVIDENCE SERIES**

In 2002, Randox invented the world's first, Biochip Array Technology, offering highly specific tests, coupled to the highly sensitive chemiluminescent detection, providing quantitative results instantly changing the landscape of diagnostic testing forever. The Randox Evidence Series of multi-analyte immunoanalyser's provide an unrivalled increase in patient information per sample offering diagnostic, prognostic and predictive solutions across a variety of disease areas with a highly advanced clinical and toxicology immunoassay test menu including cardiac, diabetes, drugs of abuse, metabolic and renal markers.

### **CONTACT US**

Contact us for more information on any of our products and services:

#### **HEADQUARTERS**

Randox Laboratories Ltd, 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom 44 (0) 28 9442 2413 reagents@randox.com

### INTERNATIONAL OFFICES



AUSTRALIA Randox (Australia) Pty Ltd. Tel: +61 (0) 2 9615 4640



**CZECH REPUBLIC** Randox Laboratories S.R.O. Tel: +420 2 1115 1661



HONG KONG Randox Laboratories Hong Kong Limited Tel: +852 3595 0515



POLAND Randox Laboratories Polska Sp. z o.o. Tel: +48 22 862 1080

REPUBLIC OF IRELAND Randox Teoranta Tel: +353 7495 22600



**SOUTH KOREA** Randox Korea Tel: +82 (0) 31 478 3121



UAE Randox Medical Equipments Trading LLC Tel: +971 55 474 9075 **BRAZIL** Randox Brasil Ltda. Tel: +55 11 5181-2024



FRANCE Laboratoires Randox Tel: +33 (0) 130 18 96 80

ITALY Randox Laboratories Ltd. Tel: +39 06 9896 8954



PORTUGAL Irlandox Laboratorios Quimica Analitica Ltda Tel: +351 22 589 8320



**SLOVAKIA** Randox S.R.O. Tel: +421 2 6381 3324



**SPAIN** Laboratorios Randox S.L. Tel: +34 93 475 09 64



USA Randox Laboratories - US, Ltd. Tel: +1 304 728 2890

### \*):

CHINA Randox Laboratories Ltd. Tel: +86 021 6288 6240



GERMANY Randox Laboratories GmbH Tel: +49 (0) 215 1937 0611



INDIA Randox Laboratories India Pvt Ltd. Tel: +91 80 6751 5000



PUERTO RICO Clinical Diagnostics of Puerto Rico, LLC Tel: +1 787 701 7000



SOUTH AFRICA Randox Laboratories SA (Pty) Ltd. Tel: +27 (0) 11 312 3590

+

SWITZERLAND Randox Laboratories Ltd. (Switzerland) Tel: +41 41 810 48 89



VIETNAM Randox Laboratories Ltd. Vietnam Tel: +84 (0) 8 3911 0904

### FOR TECHNICAL SUPPORT CONTACT:

technical.services@randox.com



Copyright © 2021 Randox Laboratories Ltd. All rights Reserved. VAT number: GB 151682708. Product availability may vary from country to country. Some products may be for Research Use Only. For more information on product application and availability, please contact your local Randox Representative